Immunomedics Reports Development of Improved Cancer Immunotherapy at the 2014 Annual Meeting of the American Society of Clinical

Immunomedics Reports Development of Improved Cancer Immunotherapy at the 2014
Annual Meeting of the American Society of Clinical Oncology

   -- T-cell Redirecting Immunotherapy Enhanced With Interferon-α in Human
                   Pancreatic and Gastric Cancer Models --

CHICAGO, June 1, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU)
today reported the development of bispecific antibodies that redirect human
T-cells to certain solid cancers.

T-cell redirected therapy of cancer is one of several new methods of cancer
immunotherapy being studied both clinically and preclinically. In contrast to
hematological tumors, little progress has been made in this approach to treat
the more challenging solid cancers, including pancreatic and gastric cancers,
two malignancies with very high rates of mortality.

The Company has previously reported the development of (E1)-3s, a novel
investigational T-cell redirecting bispecific antibody created using the
Company's patented DOCK-AND-LOCK™ protein conjugation technology, for the
potential treatment of pancreatic and gastric cancers. These and various other
solid cancers express high-levels of TROP-2, a target recognized by the
bispecific (E1)-3s, which also binds to the CD3 antigen on T cells. (E1)-3s
has previously been shown to effectively induce a potent and specific
T-cell-mediated killing of human pancreatic and gastric cancer cell lines. For
more information on (E1)-3s, please refer to the Company's press release at
http://www.immunomedics.com/pdfs/news/2014/pr04082014.pdf.

In the current study, the effect of interferon-α (IFN-α), which has
demonstrated clinical efficacy in multiple solid cancers, on the T-cell
redirecting bispecific antibody was evaluated using animal models of human
pancreatic or gastric cancer. In the gastric cancer model, treatment with a
combination of IFN-α and (E1)-3s bispecific antibody was superior to the
bispecific antibody alone (p=0.0007) in delaying the out-growth of tumor. The
combination also significantly delayed tumor growth in the pancreatic cancer
model compared to all other treatment groups (p<0.0007), including the IFN-α
only treatment group.

"We believe this is the first report of enhancing T-cell redirected cancer
immunotherapy with an immunomodulatory cytokine, such as interferon," remarked
Ms. Sullivan. "The challenge with this technology is to translate promising
clinical effects found in leukemia and lymphomas to the more resistant solid
cancers, and we have chosen to study two of the most lethal cancers,
pancreatic and gastric cancers," she added.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing
monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune disorders and other serious diseases. Immunomedics' advanced
proprietary technologies allow the Company to create humanized antibodies that
can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these
technologies, Immunomedics has built a pipeline of nine clinical-stage product
candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB),
who has worldwide rights in non-cancer indications to Immunomedics' Phase III
product candidate, epratuzumab. UCB expects Phase III data in systemic lupus
erythematosus (SLE) in the first quarter of 2015. Immunomedics is exploring
epratuzumab in oncology in collaboration with outside cancer study groups.
Immunomedics' most advanced wholly owned candidate is ^90Y-clivatuzumab
tetraxetan, which is in an ongoing Phase III registration trial in patients
with pancreatic cancer. Immunomedics' portfolio of wholly owned product
candidates also includes antibody-drug conjugates (ADCs) that are designed to
deliver a specific payload of a chemotherapeutic directly to the tumor while
reducing overall toxicity effects that typically occur when these
chemotherapeutic agents are dosed alone. Immunomedics' most advanced ADCs are
IMMU-132 and IMMU-130, which are in Phase I/II trials for a number of solid
tumors and metastatic colorectal cancer (mCRC), respectively. Immunomedics
also has a number of other product candidates that target solid tumors and
hematologic malignancies, as well as other diseases, in various stages of
clinical and pre-clinical development. These include bispecific antibodies
which have application as T-cell redirecting immunotherapies targeting cancers
and infectious diseases as well as next-generation therapies in cancer and
autoimmune disease. Immunomedics creates these bispecific antibodies using its
patented DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The Company
believes that its portfolio of intellectual property, which includes
approximately 248 active patents in the United States and more than 400
foreign patents, protects its product candidates and technologies.
Immunomedics' strength in intellectual property has resulted in the top-4
ranking in the January 2014 Patent Board scorecard in the Biotechnology
industry. For additional information on the Company, please visit its website
at www.immunomedics.com. The information on its website does not, however,
form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials (including the funding therefor, outcomes, timing or associated costs),
out-licensing arrangements (including the timing and amount of contingent
payments), forecasts of future operating results, potential collaborations,
and capital raising activities, involve significant risks and uncertainties
and actual results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are not limited
to, new product development (including clinical trials outcome and regulatory
requirements/actions), our dependence on UCB for the further development of
epratuzumab for non-cancer indications, risks associated with the outcome of
pending litigation, competitive risks to marketed products and availability of
required financing and other sources of funds on acceptable terms, if at all,
as well as the risks discussed in the Company's filings with the Securities
and Exchange Commission. The Company is not under any obligation, and the
Company expressly disclaims any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future
events or otherwise.

CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
         ccheng@immunomedics.com
 
Press spacebar to pause and continue. Press esc to stop.